Cargando…
Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage
INTRODUCTION: Results from several clinical trials suggest there is a dose–response effect for beta interferon-1a (INFβ1a) in multiple sclerosis (MS). METHODS: Our objective was to confirm these results through a retrospective analysis of patients with MS who had breakthrough disease (BD) on intramu...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338207/ https://www.ncbi.nlm.nih.gov/pubmed/35796951 http://dx.doi.org/10.1007/s40120-022-00377-1 |